Details for Patent: 6,784,197

Summary for Patent: 6,784,197

Title:	2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
Abstract:	The invention concerns 2-oxo-1-pyrrolidine derivatives of formula (I) wherein the substituents are as defined in the specification, as well as their use as pharmaceuticals. The compounds of the invention are particularly suited for treating neurological disorders such as epilepsy.
Inventor(s):	Edmond Differding, Benoît Kenda, Bénédicte Lallemand, Alain Matagne, Philippe Michel, Patrick Pasau, Patrice Talaga
Assignee:	UCB Biopharma SRL
Application Number:	US10/204,266
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,784,197
Patent Claim Types: see list of patent claims	Compound; Composition; Use;

United States Patent 6,784,197: Scope, Claims, and Landscape Analysis

United States Patent 6,784,197, granted on August 31, 2004, to Pharmasset Ltd., covers a method for treating Hepatitis C virus (HCV) infection. The patent's core claims revolve around the administration of specific nucleoside analogs, particularly 2'-deoxy-2'-fluoro-2'-methylcytidine (2'-F-2'-Me-C), alone or in combination with other antiviral agents. This analysis details the patent's scope, key claims, and the surrounding patent landscape relevant to its commercial and R&D implications.

What is the Primary Therapeutic Focus of US Patent 6,784,197?

The primary therapeutic focus of US Patent 6,784,197 is the treatment of Hepatitis C virus (HCV) infection. The patent describes methods for inhibiting HCV replication and treating associated liver disease through the administration of specific chemical compounds. The core of the invention lies in the efficacy of certain nucleoside analogs in combating the virus.

The patent specifies a method of treating an HCV infection by administering a therapeutically effective amount of a compound of Formula I.

Formula I:

      R2
       |
     O-C-R3
    / \
   C   C
  /     \
 C       C-R1
 |       |
 N       C=N
/ \     /
C   C--C
|   |  |
C---O  H

Where specific substitutions are defined for R1, R2, and R3. The most prominent embodiment described and claimed within the patent involves the compound 2'-deoxy-2'-fluoro-2'-methylcytidine (2'-F-2'-Me-C). This compound, a modified cytidine nucleoside, is central to the patent's claims for its antiviral activity against HCV.

The method also encompasses treating liver disease associated with HCV infection. This broadens the therapeutic application beyond mere viral load reduction to addressing the sequelae of chronic HCV. The patent discloses that the compounds are active against various strains of HCV, suggesting a potentially broad utility against the diverse genetic subtypes of the virus.

What are the Key Claims of US Patent 6,784,197?

The patent's claims define the legal boundaries of its protection. US Patent 6,784,197 contains several independent and dependent claims, with Claim 1 being the broadest independent claim.

Claim 1:

"A method of treating an infection with a Hepatitis C virus comprising administering to a patient a therapeutically effective amount of a compound of Formula I:

      R2
       |
     O-C-R3
    / \
   C   C
  /     \
 C       C-R1
 |       |
 N       C=N
/ \     /
C   C--C
|   |  |
C---O  H

wherein R1 is H, and R2 and R3 are independently selected from the group consisting of H and an alkyl of 1 to 4 carbons."

This claim broadly covers the administration of compounds conforming to Formula I for treating HCV. The definition of R1 as H, and R2 and R3 being independently selected from H or a 1-4 carbon alkyl group, establishes a specific chemical space.

Dependent Claims 2-14 further define the scope by specifying particular embodiments of Formula I, including the preferred compound:

• Claim 2: Specifies that R2 and R3 are methyl groups. This directly points to 2'-deoxy-2'-fluoro-2'-methylcytidine as a preferred compound.
• Claim 3: Specifies that R2 is methyl and R3 is H.
• Claim 4: Specifies that R2 is H and R3 is methyl.
• Claim 5: Specifies that R2 and R3 are H.
• Claim 6: Specifies the administration of a prodrug of a compound of Formula I. This allows for the patent protection of formulations that are converted into the active drug within the body.
• Claim 7: Specifies that the compound is 2'-deoxy-2'-fluoro-2'-methylcytidine. This is a highly specific claim for the lead compound of interest.
• Claim 8: Claims a method of treating liver disease associated with HCV.
• Claim 9: Claims a method of inhibiting HCV replication.
• Claim 10: Claims co-administration of a compound of Formula I with at least one other antiviral agent. This claim is critical for combination therapy strategies, which are common in HCV treatment.
• Claim 11: Lists specific categories of other antiviral agents for co-administration, including alpha-interferon, ribavirin, pegylated interferon, and protease inhibitors.
• Claim 12: Specifies alpha-interferon.
• Claim 13: Specifies ribavirin.
• Claim 14: Specifies pegylated interferon.

These claims collectively establish protection for the novel nucleoside analog 2'-F-2'-Me-C and its use in treating HCV, both as monotherapy and in combination with established antiviral treatments. The patent's strategy is to cover the compound itself, its various pharmaceutical forms (prodrugs), and its therapeutic applications, including combination therapies.

What is the Exclusivity Period for US Patent 6,784,197?

US Patent 6,784,197 was granted on August 31, 2004. Under standard US patent law, a utility patent typically has a term of 20 years from the filing date.

• Filing Date: The earliest disclosed filing date for this patent family is January 3, 2003 (US Provisional Application No. 60/437,748).
• Publication Date: US Patent Application Publication No. 2003/0130263 was published on July 10, 2003.
• Grant Date: August 31, 2004.

Assuming the 20-year term is based on the earliest non-provisional filing date of the utility application that led to this patent, the patent term would likely have expired around January 3, 2023. However, patent terms can be extended by the U.S. Patent and Trademark Office (USPTO) under certain circumstances, such as Patent Term Adjustment (PTA) for USPTO delays or Patent Term Extension (PTE) for regulatory review periods.

For drug patents, PTE is particularly relevant as it compensates for time lost during the Food and Drug Administration (FDA) approval process. Without specific information on PTA or PTE granted for US Patent 6,784,197, the standard expiration date would be calculated from the filing date.

Estimated Expiration: Based on a 20-year term from the earliest filing date (January 3, 2003), the patent would have expired around January 3, 2023.

It is crucial for businesses to verify the precise expiration date, including any PTA or PTE granted, through official USPTO records or specialized patent databases for definitive legal and commercial planning.

What is the Commercial Context and Significance of 2'-F-2'-Me-C?

The compound 2'-deoxy-2'-fluoro-2'-methylcytidine (2'-F-2'-Me-C) is a critical nucleoside analog that has played a significant role in the development of direct-acting antivirals (DAAs) for HCV. Its development and subsequent patenting by Pharmasset Ltd. positioned it as a potential backbone therapy.

Pharmasset Ltd. was acquired by Gilead Sciences in 2011 for approximately $11 billion, largely driven by the acquisition of Pharmasset's pipeline, which included sofosbuvir (formerly known as 'GSK608436' or 'PSI-6130' during development), a prodrug of 2'-F-2'-Me-C. Sofosbuvir, marketed as Sovaldi and as part of combination therapies like Harvoni and Epclusa, revolutionized HCV treatment due to its high efficacy, pan-genotypic activity, and improved safety profile compared to older interferon-based regimens.

The significance of 2'-F-2'-Me-C and its derivatives lies in their mechanism of action: they act as chain terminators for the viral RNA polymerase (NS5B). By mimicking natural nucleosides, they are incorporated into the growing viral RNA chain, but due to their modified structure (specifically the 2'-methyl and 2'-fluoro groups), they prevent further elongation, thereby halting viral replication.

The commercial success of sofosbuvir-based therapies, driven by compounds like 2'-F-2'-Me-C, has led to a dramatic reduction in the global burden of HCV, with cure rates exceeding 95% for many patient populations. The high acquisition price of Pharmasset and the subsequent market dominance of Gilead's HCV franchise highlight the immense commercial value protected by patents covering these novel nucleoside analogs and their therapeutic uses.

How Does the Patent Landscape for Nucleoside Analogs for HCV Treatment Evolve?

The patent landscape for nucleoside analogs in HCV treatment is characterized by extensive and overlapping claims, reflecting intense R&D efforts by multiple pharmaceutical companies. This landscape has evolved from foundational patents on nucleoside chemistry to sophisticated claims covering specific compounds, their prodrugs, formulations, manufacturing processes, and therapeutic regimens.

Key Trends and Players:

• Early Patents: Focused on broad classes of nucleoside and nucleotide analogs with potential antiviral activity. Companies like Ribapharm (later acquired by Roche), InterMune, and smaller biotechs were active.
• Nucleoside/Nucleotide Specificity: As research progressed, patents became more specific, claiming particular modifications at key positions of the nucleoside structure (e.g., 2' and 3' positions) that were found to confer potent and selective activity against HCV NS5B polymerase. Pharmasset's patents on 2'-F-2'-Me-C exemplify this.
• Prodrug Strategies: Many potent nucleoside analogs exhibit poor oral bioavailability or cellular uptake. Consequently, significant patenting activity surrounds the development of prodrugs, such as phosphoramidate prodrugs (like the one used for sofosbuvir), designed to improve pharmacokinetic properties. Gilead Sciences holds numerous patents related to sofosbuvir's prodrug forms.
• Combination Therapies: Given the viral resistance mechanisms and the desire for higher cure rates, combination therapy patents became crucial. These claims cover the co-administration of a nucleoside analog with other DAAs, such as NS3/4A protease inhibitors, NS5A inhibitors, and non-nucleoside inhibitors. Patents in this area often specify particular classes of compounds to be combined.
• Genotypic/Subtype Specificity: While many modern DAAs are pan-genotypic, earlier research may have focused on specific HCV genotypes. Patents might claim compounds or regimens effective against particular genotypes (e.g., genotype 1).
• Manufacturing and Polymorphs: As drugs approach commercialization, patents are filed for novel synthetic routes, crystalline forms (polymorphs) with improved stability or bioavailability, and specific pharmaceutical compositions.
• Key Players: Beyond Pharmasset/Gilead, significant patent portfolios in HCV DAAs have been built by companies including AbbVie, Bristol Myers Squibb, Merck, and Johnson & Johnson.

Challenges in the Landscape:

• Prior Art and Inventive Step: The dense patenting activity means that establishing novelty and inventive step for new nucleoside analogs can be challenging, requiring careful analysis of existing patents and scientific literature.
• Freedom to Operate (FTO): Companies developing new HCV therapies must conduct thorough FTO analyses to ensure their products do not infringe on existing patents covering compounds, formulations, or treatment methods.
• Patent Expiration and Generics: As patents expire, the market opens up to generic competition. The strategy for many companies is to develop next-generation therapies or to have broad patent protection that extends the exclusivity period.

The landscape for 2'-F-2'-Me-C is representative of the broader patent evolution in antiviral drug development, moving from broad therapeutic claims to highly specific molecular entities and treatment strategies.

What Are the Key Intellectual Property Considerations for Companies in This Space?

For companies operating within or adjacent to the nucleoside analog space for HCV, several key intellectual property considerations are paramount for R&D investment and strategic decision-making.

• Freedom to Operate (FTO) Analysis: A rigorous FTO analysis is essential before initiating any development. This involves a comprehensive search and review of active and pending patents to identify any claims that a new compound, formulation, or method of treatment might infringe. For 2'-F-2'-Me-C and its derivatives, this would include patents covering the core compound, its prodrug forms, specific salts, crystalline structures, and combination therapies.
• Patentability of Novel Compounds and Methods: If a company is developing new nucleoside analogs or treatment strategies, understanding the criteria for patentability (novelty, non-obviousness, utility) is critical. The bar for inventive step can be high given the extensive prior art in this field. Demonstrating significant improvements in efficacy, safety, pharmacokinetics, or overcoming resistance mechanisms is often necessary.
• Maximizing Patent Term and Scope: Strategies to maximize patent exclusivity are vital. This includes filing for Patent Term Adjustment (PTA) and Patent Term Extension (PTE) for regulatory delays, and strategically filing continuations and divisionals to cover evolving aspects of the invention. Claim drafting needs to be precise and encompass the intended commercial applications, including various formulations and combination therapies.
• Licensing and Cross-Licensing: Given the complexity of the patent landscape, licensing agreements are often necessary. Companies may need to license foundational patents on nucleoside scaffolds or specific delivery technologies. Cross-licensing can also be a strategy to gain access to essential IP from competitors.
• Enforcement and Litigation: Protecting patented innovations requires a robust enforcement strategy. This may involve monitoring the market for infringing products and initiating legal action where appropriate. Conversely, companies must be prepared to defend their patents against challenges, such as inter partes reviews (IPRs) at the USPTO or litigation in federal courts.
• Trade Secrets: Beyond patents, certain aspects of drug development, such as specific manufacturing process optimizations, know-how regarding impurity control, or formulation nuances not fully disclosed in patents, can be protected as trade secrets.
• Global Patent Strategy: Intellectual property protection is territorial. Companies must develop a coordinated global patent strategy, filing in key markets where sales are anticipated and where competitors are active. This includes understanding the nuances of patent law in different jurisdictions.

For US Patent 6,784,197 and related patents, understanding the claims' reach relative to current and emerging HCV treatments is key. For instance, patents covering specific nucleoside analogs are being superseded in relevance by patents for pan-genotypic, all-oral, short-course combination therapies, where the specific nucleoside analog might be just one component.

Key Takeaways

• US Patent 6,784,197 protects a method for treating Hepatitis C virus (HCV) infection using specific nucleoside analogs, primarily focusing on 2'-deoxy-2'-fluoro-2'-methylcytidine (2'-F-2'-Me-C).
• The patent's claims cover the administration of compounds of Formula I, including specific embodiments and combinations with other antiviral agents. Claim 7 specifically claims 2'-F-2'-Me-C.
• The patent, filed in early 2003 and granted in 2004, has an estimated expiration around early 2023, though actual expiry may vary due to Patent Term Adjustments or Extensions.
• 2'-F-2'-Me-C is the active metabolite of sofosbuvir (Sovaldi), a cornerstone of modern HCV therapy, underscoring the immense commercial value derived from this patent and its associated intellectual property.
• The patent landscape for HCV nucleoside analogs is dense and competitive, marked by continuous innovation in compound design, prodrug strategies, and combination therapies.
• Companies must prioritize comprehensive Freedom to Operate (FTO) analyses, strategic patent filing, and potentially licensing to navigate the IP complexities in this therapeutic area.

FAQs

1. What is the chemical name of the primary compound protected by US Patent 6,784,197? The primary compound is 2'-deoxy-2'-fluoro-2'-methylcytidine, often referred to as 2'-F-2'-Me-C.

2. Can generic versions of drugs based on US Patent 6,784,197 be produced now? The patent's estimated expiration is around early 2023. However, specific Patent Term Adjustments or Extensions could alter the precise date. Companies would need to verify the definitive expiry date and any other active patents covering the specific drug product, formulation, or manufacturing process.

3. Does US Patent 6,784,197 cover combination therapies for HCV? Yes, dependent claims within the patent, such as Claim 10, explicitly cover the co-administration of a compound of Formula I with at least one other antiviral agent.

4. What is the significance of the "Formula I" in the patent claims? Formula I defines a structural class of compounds that are claimed to be effective against HCV. Specific substituents at R1, R2, and R3 define particular embodiments, with 2'-F-2'-Me-C being a key example derived from these definitions.

5. What company ultimately benefited from the commercialization of drugs derived from this patent's technology? Gilead Sciences became the primary beneficiary through its acquisition of Pharmasset Ltd. in 2011, gaining control of sofosbuvir (Sovaldi) and its related combination therapies.

Citations

[1] Pharmasset Ltd. (2004). Method of treating Hepatitis C virus infection. U.S. Patent 6,784,197. Washington, DC: U.S. Patent and Trademark Office. [2] Gilead Sciences. (2011). Gilead Sciences to Acquire Pharmasset in $11 Billion Deal. Press Release. [3] U.S. Patent and Trademark Office. (n.d.). Patent Term Adjustments and Extensions. Retrieved from [USPTO website]. (Note: Specific URL varies; this is a general reference to USPTO resources on patent term calculations.)

Drugs Protected by US Patent 6,784,197

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 6,784,197

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0004297	Feb 23, 2000

PCT Information
PCT Filed	February 21, 2002	PCT Application Number:	PCT/EP01/01992
PCT Publication Date:	August 30, 2001	PCT Publication Number:	WO01/62726

International Family Members for US Patent 6,784,197

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1265862		PA2016013	Lithuania
European Patent Office	1452524		300815	Netherlands
European Patent Office	1452524		CA 2016 00013	Denmark
European Patent Office	1452524		16C1001	France
European Patent Office	1452524		1690009-4	Sweden
European Patent Office	1265862		PA2016013,C1265862	Lithuania